3D PEG-Fibrinogen Hydrogels for Direct hiPSC Cardiac Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing cardiac tissues from pluripotent stem cells are inefficient, require multiple cell handling steps, and fail to replicate the structural and functional properties of native human myocardium, limiting their use in high-throughput pharmaceutical screening and regenerative medicine applications.
Innovation Solution
The development of 3D microenvironments using PEG-fibrinogen hydrogels for direct differentiation of pluripotent stem cells, which allows for the creation of synchronously contracting cardiac tissues with mature ultrastructural features without additional cell handling steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods for producing cardiac tissues from pluripotent stem cells are used, then cardiac tissues can be produced, but the process requires multiple cell handling steps and is inefficient
Solution Approach 1:
The patent combines multiple cell handling steps into a single microfluidic device operation. The device integrates cell encapsulation, differentiation culture, and tissue formation processes into one continuous workflow, eliminating the need for separate handling steps and improving overall production efficiency.
Solution Approach 2:
The microfluidic device enables self-assembly and self-differentiation of pluripotent stem cells within the encapsulated microenvironment. The system provides controlled diffusion of nutrients and signaling molecules, allowing cells to automatically organize and differentiate into cardiac tissues without external intervention or manual handling.
2Reliability
If current methods for producing cardiac tissues from pluripotent stem cells are used, then cardiac tissues can be produced, but they fail to replicate the structural and functional properties of native human myocardium
Solution Approach 1:
The patent creates localized microenvironments within the microfluidic device that replicate specific aspects of the native myocardial structure. Each encapsulated cell cluster develops in a controlled local environment with specific nutrient gradients and signaling cues, enabling formation of tissue with authentic structural and functional properties.
Solution Approach 2:
The patent uses soluble factors and growth molecules as intermediaries to mediate cell differentiation and tissue organization. These molecular mediators are delivered through the microfluidic system to guide cells toward forming cardiac tissue with native-like properties, bridging the gap between simple cell culture and complex tissue formation.
3Reliability
If 3D microenvironments using PEG-fibrinogen hydrogels are used for direct differentiation, then synchronously contracting cardiac tissues with mature ultrastructural features can be created, but the complexity of the hydrogel system increases
Solution Approach 1:
The patent employs PEG-fibrinogen hydrogel as a composite material combining synthetic PEG polymer with natural fibrinogen protein. This composite provides both the structural integrity and biodegradability needed for 3D tissue formation, while the fibrinogen component offers cell recognition sites that promote mature ultrastructural development.
Solution Approach 2:
The patent controls the physical and chemical parameters of the PEG-fibrinogen hydrogel, such as crosslinking density, mesh size, and degradation rate, to optimize the 3D microenvironment. By adjusting these parameters, the system supports cell differentiation and tissue maturation while maintaining manageable system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of cardiac tissues with comparable CM yield, gene expression, and calcium handling properties to 2D monolayers, retaining spontaneous contractile function for several months and replicating 3D human heart development in vitro.
Implementation Method 1
Encapsulation and cardiac differentiation of hiPSCs in 3D PEG-fibrinogen hydrogels
Data Source
AI summary
The present invention relates to the production of cell cultures and tissues from undifferentiated pluripotent stem cells using three-dimensional biomimetic materials. The resultant cell cultures or tissues can be used in any of a number of protocols including testing chemicals, compounds, and drugs. Further, the methods and compositions of the present invention further provide viable cell sources and novel cell delivery platforms that allow for replacement of diseased tissue and engraftment of new cardiomyocytes from a readily available in vitro source. The present invention includes novel methods required for the successful production of cell cultures and tissues, systems and components used for the same, and methods of using the resultant cell and tissue compositions.